Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04807595 · ClinicalTrials.gov registry record
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 798
- Enrollment target
NCT04807595 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 798 participants.
The verdict
NCT04807595 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 798 participants
- Enrollment target
Study Summary
This is a worldwide, multicenter, non-interventional, retrospective study of patient medical records from metastatic breast cancer (mBC) patients previously identified as human epidermal growth factor receptor 2 negative (HER2-neg), regardless of hormone status.
Interventions
- OTHER None (Observational study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 798 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2022-04-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04807595
The ClinicalTrials.gov registry entry for NCT04807595 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 798 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which None (Observational study) is the first listed.
NCT04807595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04807595 about?
NCT04807595 is a clinical study titled "Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status". This is a worldwide, multicenter, non-interventional, retrospective study of patient medical records from metastatic breast cancer (mBC) patients previously identified as human epidermal growth factor receptor 2 negative (HER2-neg), regardless of hormone status.
What is the current status of trial NCT04807595?
This trial is currently completed. The enrollment target is 798 participants. The study started on 2021-05-28. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT04807595?
The interventions under investigation include: None (Observational study) (OTHER).
Who is sponsoring clinical trial NCT04807595?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.